{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bile+Duct+Neoplasms&page=2", "query": { "condition": "Bile Duct Neoplasms", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bile+Duct+Neoplasms&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T11:53:47.711Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04566133", "title": "Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Biliary Cancer", "Biliary Tract Neoplasms", "Cholangiocarcinoma" ], "interventions": [ { "name": "Trametinib", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-02-15", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566133" }, { "nct_id": "NCT03257761", "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extrahepatic Bile Duct Adenocarcinoma, Biliary Type", "Gallbladder Adenocarcinoma, Biliary Type", "Metastatic Pancreatic Adenocarcinoma", "Recurrent Cholangiocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage III Gallbladder Cancer AJCC V7", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage III Intrahepatic Cholangiocarcinoma AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IIIA Gallbladder Cancer AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Gallbladder Cancer AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Gallbladder Cancer AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Gallbladder Cancer AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7", "Stage IVB Gallbladder Cancer AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7", "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7", "Unresectable Gallbladder Carcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Guadecitabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2018-02-07", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 3, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257761" }, { "nct_id": "NCT06340620", "title": "EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Disease", "Pancreatic Cancer", "Pancreatic Cyst", "Gastrointestinal Tumor", "Bile Duct Diseases", "Bile Duct Cancer", "Lymph Node Disease", "Submucosal Tumor of Gastrointestinal Tract", "Gastrointestinal Cancer" ], "interventions": [ { "name": "Endoscopic ultrasound examination", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Orlando Health, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 140, "start_date": "2024-03-25", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2024-04-01", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06340620" }, { "nct_id": "NCT05712356", "title": "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cholangiocarcinoma", "Gallbladder Cancer", "Gallbladder Carcinoma", "Intrahepatic Cholangiocarcinoma", "Extrahepatic Cholangiocarcinoma", "Bile Duct Cancer", "Gall Bladder Cancer", "Gall Bladder Carcinoma" ], "interventions": [ { "name": "certepetide", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2023-05-13", "completion_date": "2026-04-05", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Merriam", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05712356" }, { "nct_id": "NCT00836992", "title": "Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anal Cancer", "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Lung Cancer", "Pancreatic Cancer", "Small Intestine Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 144, "start_date": "2009-01", "completion_date": "2015-07-27", "has_results": false, "last_update_posted_date": "2017-05-24", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00836992" }, { "nct_id": "NCT01819766", "title": "Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Inflammatory Bowel Disease (IBD)", "Primary Sclerosing Cholangitis (PSC)", "Colorectal Neoplasms", "Colorectal Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 440, "start_date": "2013-03", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-02-17", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 24, "location_summary": "Phoenix, Arizona • La Jolla, California • Miami, Florida + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01819766" }, { "nct_id": "NCT00019474", "title": "Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Liver Cancer", "Pancreatic Cancer", "Small Intestine Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "hydroxyurea", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 60, "start_date": "1998-03", "completion_date": "2000-08", "has_results": false, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019474" }, { "nct_id": "NCT01905384", "title": "Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Distal Bile Duct Obstruction" ], "interventions": [ { "name": "Covered Self-expanding metal biliary stents (C-SEMS)", "type": "DEVICE" }, { "name": "Uncovered Self-expanding metal biliary stents (U-SEMS)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2017-11-08", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 2, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01905384" }, { "nct_id": "NCT03445585", "title": "Biobank for Cholestatic Liver Diseases.", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Sclerosing Cholangitis", "Primary Biliary Cirrhosis", "Cholangiocarcinoma", "Liver Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 9150, "start_date": "2017-01", "completion_date": "2050-01", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03445585" }, { "nct_id": "NCT00005997", "title": "Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Liver Cancer" ], "interventions": [ { "name": "becatecarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "1999-04", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-06-10T11:53:47.711Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005997" } ] }